SGLT2 Inhibitors Special Populations Summary

What Is the SGLT2 Inhibitor Drug Class?

SGLT2 inhibitors are a class of oral antidiabetic and cardio-renal protective agents that block sodium-glucose cotransporter 2 in the S1 segment of the proximal renal tubule. By blocking this transporter, they prevent reabsorption of roughly 60 to 90 grams of filtered glucose per day, promoting glucosuria and osmotic diuresis. The class includes four FDA-approved agents: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro).

Approved Indications by Agent

Each agent carries a distinct FDA label. Empagliflozin holds approvals for type 2 diabetes (T2DM), heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and CKD risk reduction. Dapagliflozin is approved for T2DM, HFrEF, and CKD. Canagliflozin covers T2DM and CKD with albuminuria. Ertugliflozin is approved only for T2DM glycemic control.

The FDA prescribing information for empagliflozin specifies that the cardiovascular and renal indications do not depend on T2DM diagnosis, a distinction that broadens the eligible population considerably [1].

Mechanism Beyond Glucose Lowering

Glucosuria drives several downstream effects. Osmotic diuresis reduces preload, lowering systolic blood pressure by 3 to 5 mmHg and reducing body weight by 1 to 3 kg. Natriuresis suppresses tubuloglomerular feedback, reducing intraglomerular pressure independently of blood glucose. This hemodynamic unloading is now considered a primary driver of the heart failure and CKD benefits rather than glucose control alone [2].

Cardiovascular Special Populations

Heart Failure With Reduced Ejection Fraction

The EMPEROR-Reduced trial (N=3,730) randomized patients with HFrEF (EF <40%) to empagliflozin 10 mg or placebo. The primary composite of CV death or HF hospitalization was reduced by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001), driven substantially by a 30% reduction in first HF hospitalization [3]. The benefit appeared within 12 days of treatment initiation.

The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with symptomatic HFrEF to reduce HF hospitalization and CV death, regardless of T2DM status [4].

Heart Failure With Preserved Ejection Fraction

EMPEROR-Preserved (N=5,988) enrolled patients with EF >40%. Empagliflozin reduced the primary composite (CV death or HF hospitalization) by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) [5]. This trial represented the first pharmacotherapy to demonstrate meaningful benefit in HFpEF, a population historically resistant to drug-based outcomes improvement.

The DELIVER trial (N=6,263) confirmed dapagliflozin 10 mg produced a 18% relative risk reduction in the same composite in patients with EF >40% (HR 0.82, 95% CI 0.73 to 0.92, P<0.001) [6].

Established Atherosclerotic Cardiovascular Disease

EMPA-REG OUTCOME (N=7,020) tested empagliflozin 10 mg or 25 mg in T2DM patients with established ASCVD. CV death was reduced by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001). All-cause mortality dropped by 32% [7]. The EMPA-REG OUTCOME publication in NEJM remains a landmark reference for the class-wide cardiovascular signal [7].

CANVAS (N=10,142) showed canagliflozin reduced MACE (major adverse cardiovascular events) by 14% (HR 0.86, 95% CI 0.75 to 0.97), though it also revealed a doubling in lower-limb amputation risk (HR 1.97), a safety concern that has since been absent in CREDENCE and EMPA-REG data [8].

Chronic Kidney Disease Special Populations

Albuminuric CKD in T2DM

CREDENCE (N=4,401) enrolled T2DM patients with eGFR 30 to 90 mL/min/1.73m² and UACR >300 mg/g receiving maximum-tolerated renin-angiotensin system blockade. Canagliflozin 100 mg reduced the composite renal or CV endpoint by 30% (HR 0.70, 95% CI 0.59 to 0.82, P=0.00001) and slowed eGFR decline by approximately 2.7 mL/min/1.73m² per year versus placebo [9].

The CREDENCE trial publication in NEJM prompted the FDA to extend canagliflozin's label to include CKD risk reduction [9].

CKD Across the Spectrum (With or Without T2DM)

DAPA-CKD (N=4,304) enrolled patients with eGFR 25 to 75 mL/min/1.73m² and UACR 200 to 5000 mg/g regardless of T2DM status. Dapagliflozin 10 mg reduced the composite of sustained 50% eGFR decline, ESRD, or renal or CV death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [10]. The trial was stopped early for overwhelming efficacy. The DAPA-CKD results published in NEJM cemented dapagliflozin's renal indication beyond diabetes [10].

eGFR Thresholds for Prescribing

Glycemic efficacy diminishes as eGFR falls, because the drug's glucose-lowering depends on filtered glucose load. Current FDA labeling and the KDIGO 2022 CKD guideline provide these practical thresholds [11]:

• Empagliflozin: initiate if eGFR ≥20; glycemic effect attenuated below eGFR 45.
• Dapagliflozin: initiate for CKD if eGFR ≥25; for glycemic control, eGFR ≥45.
• Canagliflozin: for CKD indication, initiate if eGFR ≥30.
• Ertugliflozin: do not initiate if eGFR <45; discontinue if eGFR persistently <45.

The 2022 KDIGO CKD guideline states: "We recommend treatment with an SGLT2 inhibitor for adults with type 2 diabetes and CKD who have an eGFR ≥20 mL/min/1.73m²" (Grade 1A) [11].

Elderly Patients (Age 65 and Older)

Efficacy in Older Adults

Subgroup analyses from EMPEROR-Reduced and DAPA-HF both demonstrated consistent HF hospitalization and CV death reductions in patients aged 65 and older, with HRs comparable to the overall trial populations. A pooled analysis of EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 (combined N=34,322) found that the relative cardiovascular benefit from SGLT2 inhibitors did not differ significantly by age subgroup (interaction P=0.47) [12].

Safety Considerations in the Elderly

Volume depletion is the primary concern. The osmotic diuretic effect can drop systolic BP by 3 to 5 mmHg, meaningful in patients already on loop diuretics or ACE inhibitors. The FDA drug safety communication on canagliflozin recommends close monitoring for signs of dehydration, particularly in patients aged 75 and older [13].

Genital mycotic infections occur in approximately 10% of women and 4% of men treated with SGLT2 inhibitors across trial populations, a rate that does not clearly increase with age but warrants counseling regardless [14]. Patients with urinary incontinence may find the polyuria inconvenient; discussing timing of the dose (morning dosing minimizes nocturia disruption) can preserve adherence.

Fall risk secondary to orthostatic hypotension deserves assessment at each visit in patients aged 75 and older, particularly those with baseline systolic BP <110 mmHg.

Patients With Type 1 Diabetes

Off-Label Use and the DKA Risk

No SGLT2 inhibitor currently holds FDA approval for T1DM glycemic management in the United States, though sotagliflozin (a dual SGLT1/SGLT2 inhibitor) received European approval for this indication. Off-label use of dapagliflozin and empagliflozin in T1DM has been studied in DEPICT-1, DEPICT-2, and EASE-2 trials.

DEPICT-1 (N=833) showed dapagliflozin 5 mg reduced HbA1c by 0.42% versus placebo (P<0.001) over 24 weeks and cut time-above-range by approximately 1.5 hours per day [15]. The trade-off: diabetic ketoacidosis occurred in 2.6% of patients on dapagliflozin 5 mg versus 0.4% on placebo. DKA events were frequently euglycemic, making clinical recognition harder.

The FDA's 2015 Drug Safety Communication specifically flags euglycemic DKA as a risk with SGLT2 inhibitors across both T1DM and T2DM [16]. For off-label T1DM use, strict patient selection (BMI >27, well-controlled blood glucose, carbohydrate-aware patient) and ketone monitoring protocols reduce but do not eliminate this risk.

Pregnancy and Lactation

Contraindication in the Second and Third Trimesters

SGLT2 inhibitors are contraindicated during the second and third trimesters of pregnancy. Animal studies in rats and rabbits demonstrated adverse renal developmental outcomes at exposures relevant to human clinical doses. The kidney-expressed SGLT2 transporter is essential to normal fetal renal maturation [17].

The FDA prescribing label for dapagliflozin states: "FARXIGA is not recommended during the second and third trimester of pregnancy. If pregnancy is detected, FARXIGA should be discontinued as soon as possible" [17].

First-trimester exposure data in humans are limited. If a patient on an SGLT2 inhibitor discovers she is pregnant, immediate discontinuation is indicated. Insulin and metformin remain the preferred glycemic agents during pregnancy.

No adequate data exist on SGLT2 inhibitor presence in human breast milk. Given the potential for serious adverse effects on a nursing infant's renal development, breastfeeding is not recommended during SGLT2 inhibitor therapy.

Patients With Hepatic Impairment

Pharmacokinetic data show no dose adjustment is needed for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment across empagliflozin, dapagliflozin, and canagliflozin. Severe hepatic impairment (Child-Pugh C) has not been studied adequately. The canagliflozin prescribing label advises against use in severe hepatic impairment due to insufficient safety data [18].

Glucose-lowering efficacy may be partially attenuated in severe hepatic disease, where hepatic gluconeogenesis is already impaired, though the predominant mechanism of SGLT2 inhibitors is renal rather than hepatic.

Patients Undergoing Surgery or Acute Illness

Perioperative and acute illness management of SGLT2 inhibitors requires attention to DKA risk. The Joint British Diabetes Societies (JBDS) guidance, referenced by FDA communications, recommends withholding SGLT2 inhibitors at least 3 days before elective surgery [19]. During prolonged fasting, ketone production rises even when blood glucose appears controlled.

Sick-day rules should instruct patients to hold the drug during:

• Acute febrile illness with reduced oral intake
• Procedures requiring fasting >8 hours
• Significant diarrhea or vomiting lasting more than 24 hours

Post-surgery reinitiation should wait until the patient is eating and drinking normally and renal function has returned to baseline.

Patients With Recurrent Urinary Tract Infections

Glucosuria creates a substrate for bacterial growth in the urine. Across major trials, SGLT2 inhibitors increase UTI rates modestly. In EMPA-REG OUTCOME, UTI rates were 18.0% with empagliflozin versus 17.0% with placebo, a difference that was not statistically significant [7]. Genital mycotic infections, however, ran at approximately 6% versus 1% in the same dataset.

Patients with three or more UTIs per year warrant individual risk-benefit reassessment before initiating or continuing SGLT2 inhibitors. The 2023 ADA Standards of Care note that genital mycotic infections, not urinary tract infections, represent the most consistently elevated infectious adverse effect across the class [20].

Original Prescribing Framework: The SGLT2 Population-Fit Matrix

The following framework synthesizes the trial evidence and label restrictions above into a single prescribing decision reference. For each clinical scenario, the table identifies the preferred agent, the relevant trial supporting that choice, and the minimum eGFR for initiation.

| Clinical Scenario | Preferred Agent | Key Trial | Min eGFR | |---|---|---|---| | T2DM + established ASCVD | Empagliflozin 10 mg | EMPA-REG OUTCOME | ≥20 (CV benefit); ≥45 (glycemic benefit) | | HFrEF (EF <40%), any DM status | Empagliflozin or dapagliflozin | EMPEROR-Reduced / DAPA-HF | ≥20 | | HFpEF (EF ≥40%), any DM status | Empagliflozin or dapagliflozin | EMPEROR-Preserved / DELIVER | ≥20 | | T2DM + albuminuric CKD (UACR >300) | Canagliflozin 100 mg | CREDENCE | ≥30 | | CKD (any DM status, UACR ≥200) | Dapagliflozin 10 mg | DAPA-CKD | ≥25 | | T2DM glycemic control only | Any agent | DECLARE-TIMI 58 | ≥45 | | Pregnancy (2nd/3rd trimester) | Contraindicated | N/A | N/A | | Elective surgery within 3 days | Hold drug | JBDS guidance | N/A |

Monitoring Protocol Across Special Populations

Baseline and follow-up labs vary by indication. This schedule reflects guidance from the 2022 ADA Standards of Care and product labeling [21]:

Before initiation:

• eGFR, serum creatinine, UACR
• Serum potassium (especially if on ACE inhibitor, ARB, or MRA)
• Blood pressure, weight
• Urinalysis to exclude active UTI
• Pregnancy test if appropriate

At 4 weeks:

• eGFR and creatinine (expected transient 5 to 10% dip from hemodynamic effect)
• Blood pressure and symptoms of volume depletion
• Assess for genital symptoms

Every 3 to 6 months:

• HbA1c (if diabetic indication)
• eGFR and UACR
• Body weight and blood pressure

The transient eGFR dip seen at initiation is a hemodynamic effect, not nephrotoxicity. A dip of up to 30% followed by stabilization predicts long-term renal protection, a pattern replicated in both CREDENCE and DAPA-CKD [9, 10].